CDK4/CRBN PROTAC Binding Detection Kit: A Core Evaluation Tool for Targeted Degradation of Cell Cycle Kinases

Author: Senior Product Manager of UA Views：10

This article focuses on the molecular function of CDK4 and PROTAC-targeted degradation strategies, systematically elucidating the core mechanisms of the CDK4/6-cyclin D complex in regulating cell cycle progression and its aberrant activation characteristics in tumor cells. It analyzes the non-cell cycle functions of CDK4 in modulating tumor metabolism and anti-tumor immune responses, and explores the novel pathways provided by CRBN-based PROTAC technology for targeted degradation of CDK4.

Recent Advances
Product Information

Recent Advances

CDK4 CRBN PROTAC Binding Detection Kit: A Core Evaluation Tool for Targeted Degradation of Cell Cycle Kinases

Overview
This article systematically elaborates on the core mechanisms of the CDK4/6-cyclin D complex in regulating cell cycle progression and its aberrant activation characteristics in tumor cells, analyzes the non-cell cycle functions of CDK4 in regulating tumor metabolism and anti-tumor immune responses, and explores the new pathways provided by CRBN-based PROTAC technology for targeted degradation of CDK4.

I. Core Mechanisms of CDK4/6 in Regulating Cell Cycle Progression

The most well-documented function of CDK4/6 is to phosphorylate retinoblastoma proteins, including RB1 and RB-like proteins RBL1 and RBL2, by binding to cyclin D, ultimately activating the E2F transcription program and promoting cell entry into the S phase of the cell cycle. In normal cells, the activity of CDK4/6 and cyclin D is strictly regulated by extracellular mitogenic signals. However, in tumor cells, due to activating mutations, the protein kinase remains in an activated state, allowing cell division to proceed uncontrolled by proliferation and inhibitory signals. This mechanism forms the molecular basis for CDK4/6 as a target for anti-tumor drugs.

Among the inhibitors developed based on CDK4/6 inhibition, three have been approved by the U.S. FDA for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. Additionally, CDK4/6 inhibitors have been approved by the FDA to reduce the frequency of myelosuppression in patients with extensive-stage small cell lung cancer receiving certain types of chemotherapy. These clinical advancements validate the druggability of CDK4/6 as a drug target while also driving deeper exploration of their biological functions.

II. Role of CDK4 in Regulating Tumor Cell Metabolism

Recent studies have begun to reveal the non-cell cycle roles of CDK4/6. Current research results indicate that it also plays an important role in regulating cancer cell metabolism and anti-tumor immune responses.

Treatment of pancreatic cancer cells with CDK4/6 inhibitors leads to metabolic reprogramming of tumor cells, resulting in increased numbers of mitochondria and lysosomes, activation of the mTOR signaling pathway, and enhanced oxidative phosphorylation. Combining CDK4/6 inhibitors with mTOR inhibitors can strongly inhibit tumor cell proliferation. However, inhibition of CDK4/6 activity may increase the number of lysosomes in tumor cells, and the increase in lysosome number is a cause of resistance to certain CDK4/6 inhibitors, which may reduce the clinical benefits of these inhibitors.

Cyclin D3 and CDK6 promote the production of the antioxidants NADPH and GSH, which help neutralize reactive oxygen species. Treatment of tumors highly expressing cyclin D3 and CDK6 with CDK4/6 inhibitors depletes NADPH and GSH, increases ROS levels, and induces apoptosis. Another link between CDK4/6 and metabolism and cancer is the observed increase in cyclin D1 expression levels in obese or diabetic mice. Using anti-diabetic drugs to reduce cyclin D1 levels in liver cells can decrease the incidence of hepatocellular carcinoma in mice. This observation suggests the possibility of combining anti-diabetic drugs with CDK4/6 inhibitors to treat liver cancer in obese patients.

III. Regulation of Anti-Tumor Immune Responses by CDK4/6 Inhibitors

CDK4/6 inhibitors can regulate anti-tumor immune responses through direct effects on tumor cells and influences on the tumor immune environment. In breast cancer tumor models, CDK4/6 inhibitors can activate endogenous retroviral elements in tumor cells, leading to increased levels of double-stranded RNA. This stimulates the production of type III interferons and enhances tumor antigen presentation. Thus, CDK4/6 inhibitors can activate antiviral immune responses by inducing viral gene expression, aiding in tumor elimination.

Inhibition of CDK4/6 activity can also affect the immune system by impeding the proliferation of CD4-positive FOXP3-positive regulatory T cells (Tregs). Tregs typically suppress anti-tumor immune responses. Since cytotoxic CD8-positive T cells are less affected by CDK4/6 inhibitors, previous studies have shown that CDK4/6 inhibitors can reduce intratumoral T cells.

In triple-negative breast cancer models, the combination of CDK4/6 inhibitors with PI3K inhibitors upregulates immune-related signaling pathways in tumor cells, including proteins related to antigen presentation, thereby enhancing tumor immunogenicity. These studies collectively demonstrate that CDK4/6 inhibitors may convert "cold" tumors into "hot" tumors. The authors note that the current priority is to validate these findings in clinical trials.

IV. New Pathways for Targeted Degradation of CDK4 Provided by PROTAC Technology

Proteolysis-targeting chimeras (PROTACs) utilize the ubiquitin-proteasome system to deliver target proteins to the proteasome for degradation. Unlike traditional small-molecule inhibitors that block protein function by occupying active sites, PROTAC molecules bind the target protein at one end and recruit an E3 ligase at the other, forming a target protein-PROTAC-E3 ligase ternary complex that mediates polyubiquitination and degradation of the target protein.

For the CDK4 target, PROTAC technology provides a degradation strategy independent of kinase activity inhibition. CDK4 not only has kinase-dependent functions but also participates in regulating tumor metabolism and the immune microenvironment. Traditional CDK4/6 inhibitors primarily target its kinase activity, while PROTAC technology can completely eliminate its multiple functions by degrading the CDK4 protein. CRBN-based PROTAC molecules recruit the CRBN E3 ligase to achieve targeted degradation of CDK4, showing potential in preclinical studies of various tumor models. The ability to form ternary complexes is a key parameter determining PROTAC degradation efficiency, making it crucial to establish efficient and reliable binding detection methods at this stage.

V. Conclusion

In practical applications of CDK4-targeted degradation research, high-quality binding detection reagents are key to ensuring data reliability and experimental reproducibility. To meet the needs of evaluating CDK4/CRBN PROTAC ternary complexes, UniOne provides the UniOne® TR-FRET Human CDK4/CRBN PROTAC Binding Kit. This product is based on TR-FRET detection technology and has the following core features: utilizes the long fluorescence lifetime of lanthanide donors to effectively reduce background interference through delayed detection; homogeneous operation mode requires no washing or separation steps and is compatible with high-throughput formats in 96- and 384-well plates; stable signals support batch processing and flexible time windows; suitable for quantitative detection of PROTAC-induced ternary complex formation between CDK4 and CRBN. This kit is applicable to screening and ranking bridging activity of CDK4-targeted PROTAC molecules, linker optimization, structure-activity relationship analysis, and CRBN ligand selectivity evaluation.

As a core kinase in cell cycle regulation, CDK4 drives cell cycle progression by binding to cyclin D and phosphorylating retinoblastoma proteins. Recent studies have further revealed the non-cell cycle functions of CDK4 in regulating tumor cell metabolism and anti-tumor immune responses, making it a drug target with multiple therapeutic values. CRBN-based PROTAC technology provides a new intervention pathway by inducing selective degradation of the CDK4 protein, completely eliminating its kinase-dependent and non-kinase-dependent functions. The UniOne® TR-FRET Human CDK4/CRBN PROTAC Binding Kit provides a reliable tool for binding detection of CDK4-targeted PROTAC molecules, continuously driving innovation in the field of CDK4-targeted drug development.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose Nanjing UA-Bio

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UA Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Next